Key result
B-type natriuretic peptide is evaluated as a promising biomarker in adults with congenital heart disease.
Why the study?
Is B-type natriuretic peptide a promising biomarker in Adults with CHD?
Is B-type natriuretic peptide a promising biomarker in Adults with CHD?
This paper discusses the potential of B-type natriuretic peptide as a biomarker in adults with congenital heart disease.
Answers are grounded in this paper and cite their sources.
Adult CHD prevalence data are sparse; leaves open accurate service planning and prospective registries.
Congenital heart disease (CHD) is the most common birth defect worldwide with an estimated incidence of 9.5 per 1000 individuals globally [1, 2]. Prevalence of Adults with Congenital Heart Disease ...
No takes yet. Share an insight, caveat, or question.
Shahid et al. (2024) studied this question. B-type natriuretic peptide is evaluated as a promising biomarker in adults with congenital heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: